Clinical Outcome in Aggressively Treated Meningeal Carcinomatosis

Helical tomotherapy in patients with leptomeningeal metastases

“……”

Helical tomotherapy in patients with leptomeningeal metastases

“……”

Carcinoma Meningitis Secondary to Non–Small Cell Lung Cancer

“…Wasserstrom et al reported a 50% response rate and a median survival of 4 months in patients with both small cell and non-small cell lung primaries. These findings are similar to those of 2 other large studies 25,26 of carcinomatous meningitis in which 25 and 10 patients with non-small cell lung cancer and LM were reported, respectively; however, median survival in both of these studies (1.5 and 2.5 months, respectively) was considerably shorter. These data, and ours, suggest that patients with non-small cell lung cancer complicated by LM can be palliated with aggressive multimodal therapy; however, determining which patients are candidates for aggressive therapy is problematic.…”

“…A provocative study by Siegal et al 16 suggests a subset of patients with LM, predominantly patients with lymphoma or breast cancer, may respond to standard-dose systemic chemotherapy without the inclusion of intra-CSF therapy. Similar conclusions were reached by others, [23][24][25] suggesting the importance of systemic chemotherapy in treating patients with LM. These studies are sufficiently compelling to suggest a prospective study comparing patients with LM treated with systemic chemotherapy with or without intra-CSF chemotherapy.…”

Bilateral vestibular failure as a unique presenting sign in carcinomatous meningitis: case report

“…Despite aggressive therapy, most patients die within 6 months of diagnosis, the median survival being 6–16 weeks 7. It has been reported that response after 2 weeks of therapy is correlated with survival 7. Unfortunately, our patient did not respond to therapy.…”

Helical tomotherapy in patients with leptomeningeal metastases

“……”

Carcinoma Meningitis Secondary to Non–Small Cell Lung Cancer

“…Wasserstrom et al reported a 50% response rate and a median survival of 4 months in patients with both small cell and non-small cell lung primaries. These findings are similar to those of 2 other large studies 25,26 of carcinomatous meningitis in which 25 and 10 patients with non-small cell lung cancer and LM were reported, respectively; however, median survival in both of these studies (1.5 and 2.5 months, respectively) was considerably shorter. These data, and ours, suggest that patients with non-small cell lung cancer complicated by LM can be palliated with aggressive multimodal therapy; however, determining which patients are candidates for aggressive therapy is problematic.…”

“…A provocative study by Siegal et al 16 suggests a subset of patients with LM, predominantly patients with lymphoma or breast cancer, may respond to standard-dose systemic chemotherapy without the inclusion of intra-CSF therapy. Similar conclusions were reached by others, [23][24][25] suggesting the importance of systemic chemotherapy in treating patients with LM. These studies are sufficiently compelling to suggest a prospective study comparing patients with LM treated with systemic chemotherapy with or without intra-CSF chemotherapy.…”

Bilateral vestibular failure as a unique presenting sign in carcinomatous meningitis: case report

“…Despite aggressive therapy, most patients die within 6 months of diagnosis, the median survival being 6–16 weeks 7. It has been reported that response after 2 weeks of therapy is correlated with survival 7. Unfortunately, our patient did not respond to therapy.…”

Helical tomotherapy in patients with leptomeningeal metastases

“……”

Carcinoma Meningitis Secondary to Non–Small Cell Lung Cancer

“…Wasserstrom et al reported a 50% response rate and a median survival of 4 months in patients with both small cell and non-small cell lung primaries. These findings are similar to those of 2 other large studies 25,26 of carcinomatous meningitis in which 25 and 10 patients with non-small cell lung cancer and LM were reported, respectively; however, median survival in both of these studies (1.5 and 2.5 months, respectively) was considerably shorter. These data, and ours, suggest that patients with non-small cell lung cancer complicated by LM can be palliated with aggressive multimodal therapy; however, determining which patients are candidates for aggressive therapy is problematic.…”

“…A provocative study by Siegal et al 16 suggests a subset of patients with LM, predominantly patients with lymphoma or breast cancer, may respond to standard-dose systemic chemotherapy without the inclusion of intra-CSF therapy. Similar conclusions were reached by others, [23][24][25] suggesting the importance of systemic chemotherapy in treating patients with LM. These studies are sufficiently compelling to suggest a prospective study comparing patients with LM treated with systemic chemotherapy with or without intra-CSF chemotherapy.…”

Bilateral vestibular failure as a unique presenting sign in carcinomatous meningitis: case report

“…Despite aggressive therapy, most patients die within 6 months of diagnosis, the median survival being 6–16 weeks 7. It has been reported that response after 2 weeks of therapy is correlated with survival 7. Unfortunately, our patient did not respond to therapy.…”